BioMedNewsBreaks Archive - Page 8 of 275

ThursdayMay 28, 2026 12:35 pm

BioMedNewsBreaks — Jupiter Neurosciences Inc. (NASDAQ: JUNS) Closes $2 Million Registered Direct Offering

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering with gross proceeds of approximately $2.0 million. D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted pursuant to the company’s effective shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. To view the full press release, visit https://ibn.fm/uymqO About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company…

ThursdayMay 28, 2026 10:35 am

BioMedNewsBreaks — VERAXA Biotech AG Secures $27.5 Million Senior Secured Financing and $50 Million Equity Line Ahead of Planned Nasdaq Listing

VERAXA Biotech, a portfolio company of Xlife Sciences AG (SIX: XLS), secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement providing access to up to $50 million in equity financing with Lincoln Park Capital Fund LLC. The financing arrangements are intended to strengthen VERAXA’s financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market. The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share, while the…

ThursdayMay 28, 2026 10:11 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration…

WednesdayMay 27, 2026 11:30 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio

VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use. To view the full press release, visit https://ibn.fm/nX9FK About Volition Volition is a multi-national company focused on…

WednesdayMay 27, 2026 11:23 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Gains DTC Eligibility, Engages IBN for Investor Awareness Campaign

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company, a move expected to simplify trading for U.S. investors and enhance liquidity of the company’s shares. CEO Louis Dron said DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement. The company also announced it has engaged InvestorBrandNetwork to provide market awareness, corporate communications and digital media services, including editorial coverage, newsletter distribution, social media support and podcast syndication through Sept. 30, 2026,…

WednesdayMay 27, 2026 10:36 am

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company’s position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales. The commissioned report cites Optimi’s regulatory licenses, existing MDMA and psilocybin manufacturing capacity, expanding commercial activity in Australia and longer-term U.S. optionality, while outlining an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi’s asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development…

WednesdayMay 27, 2026 9:30 am

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes. To view the full press release, visit https://ibn.fm/qFRHu About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes…

TuesdayMay 26, 2026 11:46 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Collaborates with Resilience Biosciences on AI-Driven Drug Discovery

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced a collaboration with Resilience Biosciences Inc. to support the development and evaluation of AI-assisted computational chemistry workflows for small-molecule drug development, with the goal of improving efficiency in identifying, analyzing and advancing potential drug candidates. The collaboration will apply Redwood’s computational chemistry, cheminformatics and synthetic route design capabilities to support Resilience’s non-opioid therapeutic development programs, including workflows for derivative generation, patentability and freedom-to-operate analysis, and retrosynthetic planning aimed at accelerating early-stage drug discovery and development. To view the full press release, visit https://ibn.fm/CmioF About Redwood AI Corp. Redwood…

TuesdayMay 26, 2026 11:25 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Advances Manufacturing Scale-Up for Lead Oncology Candidate ONC010

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) reported continued progress in intermediate-scale manufacturing and process development activities for key precursor components supporting ONC010, the company’s lead nanoparticle-formulated oncology candidate currently advancing through IND-enabling development. The work, being conducted with Dalton Pharma Services as part of Onco’s integrated chemistry, manufacturing and controls strategy, is focused on process optimization, analytical characterization and manufacturing reproducibility to support future GMP production, regulatory readiness and planned first-in-human clinical development activities in Australia. To view the full press release, visit https://ibn.fm/Unt8n About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer…

FridayMay 22, 2026 3:28 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,”…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Jupiter Neurosciences Inc. (NASDAQ: JUNS) Closes $2 Million Registered Direct Offering

BioMedNewsBreaks — VERAXA Biotech AG Secures $27.5 Million Senior Secured Financing and $50 Million Equity Line Ahead of Planned Nasdaq Listing

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Gains DTC Eligibility, Engages IBN for Investor Awareness Campaign

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Collaborates with Resilience Biosciences on AI-Driven Drug Discovery

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Advances Manufacturing Scale-Up for Lead Oncology Candidate ONC010

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search